SOD1 and amyotrophic lateral sclerosis: Because of the high incidence of SOD1 mutations, which account for 20–25% of FALS cases, SOD1 has been one of the most intensely studied genes in the ALS field and continues to be a primary therapeutic target (Bosco and Landers, 2010).